Systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease

Open access

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) lead to a significant decrease in pulmonary function and quality of life and an increase in mortality. However, systemic use of corticosteroids is able to improve the conditions of patients in AECOPD. By a short review of several clinical trials, we suggest that 40 mg prednisone per day for 5 days should be recommended for the treatment of AECOPD with a preference for oral prednisolone.

References

  • 1. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013;309:2223-31.

  • 2. Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F, et al. Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J 2014;43:717-24.

  • 3. Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:1052-64.